Elsevier now offers a series of derivative works based on the acclaimed Meyler’s Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician. There has been significant progress in the development of targeted therapy drugs that act specifically on certain cancers, and that minimize damage to normal cells. Oncologists and cancer researchers will rely on this volume to determine effective drug treatments.
Les mer
Suitable for oncologists and cancer researchers, this work helps to determine effective drug treatments. It features not only anticancer drugs, but also other drugs that act upon related organ systems affected by cancer.
Les mer
Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer
Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer
The only drug guide that includes clinical case studies and expert analysis UNIQUE! Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer Most complete cross referencing of drug-drug interactions available Latest content from the most highly regarded compilation of drug side effects: Side Effects of Drugs Annual serial
Les mer

Produktdetaljer

ISBN
9780444532671
Publisert
2010-04-19
Utgiver
Vendor
Elsevier Science Ltd
Vekt
2070 gr
Høyde
276 mm
Bredde
215 mm
Aldersnivå
P, 06
Språk
Product language
Engelsk
Format
Product format
Innbundet
Antall sider
780

Redaktør

Biographical note

Dr Jeffrey K. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust. He has been associated with the Meyler series since 1977 and has published many research papers on adverse drug reactions. He is President of the British Pharmacological Society and serves on many committees concerned with drug therapy, including the Technology Appraisal Committee of the UK’s National Institute for Health and Clinical Excellence (NICE) and the Joint Formulary Committees of the British National Formulary and the British National Formulary for Children.